Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD)

被引：0

作者：

McMurray, John J. ^{[1
]}

Wheeler, David C. ^{[2
]}

Stefansson, Bergur V. ^{[3
]}

Rotter, Ricardo Correa ^{[4
]}

Chertow, Glenn M. ^{[5
,6
]}

Greene, Tom ^{[7
]}

Hou, Fan Fan ^{[8
,9
]}

Lindberg, Magnus B. ^{[10
]}

Rossing, Peter ^{[11
,12
]}

Sjostrom, David ^{[3
]}

Toto, Robert D. ^{[13
]}

Langkilde, Anna Maria ^{[3
]}

Heerspink, Hiddo J. Lambers ^{[14
]}

机构：

[1] Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland

[2] UCL, Dept Renal Med, London, England

[3] AstraZeneca, Biopharmaceut R&D, Late Stage DevCardiovasc Renal & Metab CVRM, Gothenburg, Sweden

[4] Natl Med Sci & Nutr Inst Salvador Zubiran, Mexico City, DF, Mexico

[5] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA

[6] Stanford Univ, Sch Med, Dept Epidemiol & Populat Hlth, Stanford, CA 94305 USA

[7] Univ Utah Hlth Sci, Study Design & Biostat Ctr, Salt Lake City, UT USA

[8] Nanfang Hosp, Div Nephrol, Guangzhou, Guangdong, Peoples R China

[9] Southern Med Univ, Guangzhou, Guangdong, Peoples R China

[10] AstraZeneca, Biopharmaceut R&D, Late Stage Dev Cardiovas Renal & Metab CVRM, Gothenburg, Sweden

[11] Steno Diabet Ctr, Dept Clin Med, Copenhagen, Denmark

[12] Univ Copenhagen, Copenhagen, Denmark

[13] UT Southwestern Med Ctr, Dept Internal Med, Dallas, TX USA

[14] Univ Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands

来源：

CIRCULATION | 2020年 / 142卷 / 24期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

18650

引用

页码：E482 / E483

页数：2

共 50 条

[1] Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD)
McMurray, John J. V.
Wheeler, David C.
Stefansson, Bergur V.
Correa-Rotter, Ricardo
Chertow, Glenn M.
Greene, Tom
Hou, Fan Fan
Lindberg, Magnus B.
Rossing, Peter
Sjostrom, C. David
Toto, Robert D.
Langkilde, Ann Maria
Heerspink, Hiddo J. L.
[J]. JOURNAL OF CARDIAC FAILURE, 2020, 26 (12) : 1111 - 1111
[2] The dapagliflozin and prevention of adverse outcomes in chronic kidney disease: results of the DAPA-CKD study
Batyushin, Mikhail M.
[J]. TERAPEVTICHESKII ARKHIV, 2021, 93 (06): : 713 - 723
[3] The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
Wheeler, David C.
Stefansson, Bergur, V
Batiushin, Mikhail
Bilchenko, Oleksandr
Cherney, David Z., I
Chertow, Glenn M.
Douthat, Walter
Dwyer, Jamie P.
Escudero, Elizabeth
Pecoits-Filho, Roberto
Furuland, Hans
Gorriz, Jose Luis
Greene, Tom
Haller, Hermann
Hou, Fan Fan
Kang, Shin-Wook
Isidto, Rey
Khullar, Dinesh
Mark, Patrick B.
McMurray, John J., V
Kashihara, Naoki
Nowicki, Michal
Persson, Frederik
Correa-Rotter, Ricardo
Rossing, Peter
Toto, Robert D.
Umanath, Kausik
Van Bui, Pham
Wittmann, Istvan
Lindberg, Magnus
Sjostrom, C. David
Langkilde, Anna Maria
Heerspink, Hiddo J. L.
[J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 (10) : 1700 - 1711
[4] Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
Heerspink, Hiddo J. L.
Stefansson, Bergur, V
Chertow, Glenn M.
Correa-Rotter, Ricardo
Greene, Tom
Hou, Fan-Fan
Lindberg, Magnus
McMurray, John
Rossing, Peter
Toto, Roberto
Langkilde, Anna Maria
Wheeler, David C.
[J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 (02) : 274 - 282
[5] Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial
Wheeler, David C.
Jongs, Niels
Stefansson, Bergur, V
Chertow, Glenn M.
Greene, Tom
Hou, Fan Fan
Langkilde, Anna Maria
McMurray, John J., V
Rossing, Peter
Nowicki, Michal
Wittmann, Istvan
Correa-Rotter, Ricardo
Sjostrom, C. David
Toto, Robert D.
Heerspink, Hiddo J. L.
[J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 (09) : 1647 - 1656
[6] Dapagliflozin in chronic kidney disease: cost-effectiveness beyond the DAPA-CKD trial
McEwan, Phil
Davis, Jason A.
Gabb, Peter D.
Wheeler, David C.
Rossing, Peter
Chertow, Glenn M.
Correa-Rotter, Ricardo
Tamura, Kouichi
Barone, Salvatore
Sanchez, Juan Jose Garcia
[J]. CLINICAL KIDNEY JOURNAL, 2024, 17 (02)
[7] A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function
Heerspink, Hiddo J. L.
Cherney, David
Postmus, Douwe
Stefansson, Bergur, V
Chertow, Glenn M.
Dwyer, Jamie P.
Greene, Tom
Kosiborod, Mikhail
Langkilde, Anna Maria
McMurray, John J., V
Correa-Rotter, Ricardo
Rossing, Peter
Sjostrom, C. David
Toto, Robert D.
Wheeler, David C.
[J]. KIDNEY INTERNATIONAL, 2022, 101 (01) : 174 - 184
[8] Dapagliflozin, advanced chronic kidney disease, and mortality: new insights from the DAPA-CKD trial
Marx, Nikolaus
Floege, Juergen
[J]. EUROPEAN HEART JOURNAL, 2021, 42 (13) : 1228 - 1230
[9] Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease: A Post Hoc Analysis of DAPA-CKD
Schechter, Meir
Jongs, Niels
Chertow, Glenn M.
Mosenzon, Ofri
McMurray, John J., V
Correa-Rotter, Ricardo
Rossing, Peter
Langkilde, Anna Maria
Sjostrom, C. David
Toto, Robert D.
Wheeler, David C.
Heerspink, Hiddo J. L.
[J]. ANNALS OF INTERNAL MEDICINE, 2023, 176 (01) : 59 - +
[10] Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA-CKD Trial
Chertow, Glenn M.
Correa-Rotter, Ricardo
Vart, Priya
Jongs, Niels
McMurray, John J. V.
Rossing, Peter
Langkilde, Anna Maria
Sjostrom, C. David
Toto, Robert D.
Wheeler, David C.
Heerspink, Hiddo J. L.
[J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2023, 12 (09):

← 1 2 3 4 5 →